Kidney cancer, version 3.2015.

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.

• Authors: Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B Bolger, Sam S Chang, Toni K Choueiri, Brian A Costello, Ithaar H Derweesh, Shilpa Gupta, Steven L Hancock, Jenny J Kim, Timothy M Kuzel, Elaine T Lam, Clayton Lau, Ellis G Levine, Daniel W Lin, M Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R Plimack, Edward N Rampersaud, Bruce G Redman, Charles J Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B Wilder, Mary Dwyer, Rashmi Kumar, National comprehensive cancer network
• Journal: Journal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 13 Issue 2 Pg. 151-9 (Feb 2015) ISSN: 1540-1413 [Electronic] United States
• PMID: 25691606 (Publication Type: Journal Article, Practice Guideline)
• Copyright: Copyright © 2015 by the National Comprehensive Cancer Network.

Chemical References

• Imidazoles
• Indazoles
• Protein Kinase Inhibitors
• Pyrimidines
• Sulfonamides
• pazopanib
• Axitinib

Topics

• Axitinib
• Carcinoma, Renal Cell (diagnosis, drug therapy)
• Humans
• Imidazoles (therapeutic use)
• Indazoles (therapeutic use)
• Kidney Neoplasms (diagnosis, drug therapy)
• Protein Kinase Inhibitors (therapeutic use)
• Pyrimidines (therapeutic use)
• Sulfonamides (therapeutic use)